Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFfIcacy and Tolerability of FIXed Duration Teclistamab and Talquetamab FOR FRAIL Patients With Newly Diagnosed Multiple Myeloma (2 Cohort Study) - the EMN 37 FITFIX FOR FRAIL Trial

NCT07107529 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT07107529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFfIcacy and Tolerability of FIXed Duration Teclistamab and Talquetamab FOR FRAIL Patients With Newly Diagnosed Multiple Myeloma (2 Cohort Study) - the EMN 37 FITFIX FOR FRAIL Trial
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 2
Overall status
Recruiting
Start date
December 12, 2025
Completion date
February 28, 2034
Enrollment
150 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma (mm)